Alzheimer Combination Therapies: Overview and Scenarios.

Area of Science:

• Neuroscience
• Pharmacology
• Biotechnology

Background:

• Alzheimer's disease (AD) complexity necessitates advanced therapeutic strategies.
• Current anti-amyloid monoclonal antibodies offer a 30% slowing of disease progression.
• Combination therapies represent the next frontier in AD treatment development.

Purpose of the Study:

• To explore diverse approaches for developing effective Alzheimer's disease combination therapies.
• To outline strategies for the nonclinical and clinical development of combination treatments.
• To identify potential therapeutic targets beyond amyloid pathology for combination approaches.

Main Methods:

• Review of current AD therapeutic landscape and combination therapy development pathways.
• Discussion of nonclinical assessment methods, including animal models and new approach methodologies (e.g., organoids).
• Outline of clinical trial designs (Phase 1-3) for evaluating novel drug combinations.

Main Results:

• Combination therapies can integrate various modalities like small molecules, biologics, gene therapy, and lifestyle interventions.
• Future combination strategies can target tau, inflammation, neurodegeneration, and co-pathologies.
• Computational strategies and real-world data can accelerate candidate prioritization.

Conclusions:

• Combination therapies hold significant potential to prevent or slow Alzheimer's disease progression.
• Strategic development, including target selection and robust clinical trial design, is key.
• Integrating diverse therapeutic modalities and computational approaches will advance AD treatment.